摘要
目的:探讨卡维地洛对扩张型心肌病(DCM)患者血清心肌β_1和M_2受体自身抗体的影响。方法:50例DCM患者随机分为卡维地洛治疗组和常规治疗对照组,随访6个月,观察两组的心功能和血清两种自身抗体的变化情况。结果:两组治疗后较治疗前心脏的左室收缩末径、左室舒张末径均减小,左室射血分数增加,心功能NYHA分级改善(P<0.01),卡维地洛组较常规组更明显(P<0.05)。卡维地洛组心肌β_1和M_2受体自身抗体滴度较治疗前明显降低(P<0.01),常规组治疗前后两种自身抗体滴度有下降趋势,但无显著差异(P>0.05)。结论:卡维地洛可能通过阻断心肌β_1和M_2受体自身抗体时心脏的不利作用抑制DCM患者的心室重塑,改善心功能。
Objective：To explore the effect of carvedilol on serum autoantibodies against the cardiac β1 and M2 receptor in patients with idiopathic dilated cardiomyopathy. Methods：Fifty patients with idiopathic dilated cardiomyopathy were randomly divided into carvedilol group and routine therapeutic control group and followed 6 months. The changes on cardiac function and two kinds of serum autoantibodies were observed. Results：LVESD and LVEDD decreased,LVEF increased and NYHA stage improved significantly in both groups （ P 〈 0.01）after 6 months treatment while these changes were greater in carvedilol group than in routine therapeutic control group （ P 〈 0.05）. Average titer of autoantibodies against the cardiac β1 and M2 receptor decreased significantly in carvedilol group （ P 〈 0.01） after 6 months treatment but no significant difference was found in routine therapeutic control group （ P 〉 0.05） after treatment. Conclusion： Carvedilol improved left ventricular remodeling and cardiac function by blocking the effect of serum autoantibodies against the cardiac β1 and M2 receptor in patients with idiopathic dilated cardiomyopathy.
出处
《长治医学院学报》
2007年第5期346-348,共3页
Journal of Changzhi Medical College
基金
山西省教育厅科技研发项目(20041241)
关键词
卡维地洛
扩张型心肌病
Β1受体
M2受体
自身抗体
Carvedilol
Idiopathic dilated cardiomyopathy
β1 - receptor
M2 - receptor
Autoantibodie
